ArticleAmerican journal of translational research2026
Combined use of clopidogrel and atorvastatin for angina pectoris caused by coronary heart disease: clinical effectiveness, safety, and contributing factors.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the combined use of Clopidogrel (CLO) and Atorvastatin (ATO) in patients with angina pectoris caused by coronary heart disease (CHD-AP), focusing on clinical effectiveness, safety, and contributing factors.
methodsA total of 178 CHD-AP patients admitted to Shaanxi Provincial People's Hospital between October 2022 and October 2025 were retrospectively analyzed. Based on their medication regimens, patients were categorized int an ATO+Acetylsalicylic Acid (ASA) group (n=88), receiving ATO plus ASA therapy, and an ATO+CLO group (n=90), receiving ATO+CLO treatment. Inter-group comparative assessments included clinical efficacy, safety, cardiac function measurements, serum myocardial injury markers, lipid profile (high-/low-density lipoprotein cholesterol [HDL-C/LDL-C], triacylglycerol [TG], total cholesterol [TG]), and hemorheology indices (e.g., plasma viscosity, whole blood viscosity). Factors influencing therapeutic outcomes were further explored using multivariate analysis.
resultsThe ATO+CLO group demonstrated higher overall clinical efficacy and comparable adverse reaction rates compared to the ATO+ASA group. Moreover, the ATO+CLO group showed greater improvement in cardiac function indices and HDL-C levels after treatment, as well as lower levels of various serum myocardial markers, LDL-C, TG, TC, and hemorheology indices compared to the ATO+ASA group. Multivariate analysis identified Canadian Cardiovascular Society (CCS) angina grading, cardiac index [CI], and medication regimen as independent predictors of therapeutic effects.
conclusionThe combination of CLO and ATO is effective and safe for CHD-AP patients, providing superior clinical benefits without increasing the risk of adverse reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.